Cecilia Berardi1, David A Bluemke2, Brian A Houston3, Todd M Kolb4, João A Lima5, Theo Pezel5, Ryan J Tedford3, Samuel G Rayner6, Richard K Cheng1, Peter J Leary7. 1. Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington. 2. Department of Radiology, University of Wisconsin, Madison, Wisconsin. 3. Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina. 4. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medicine, Baltimore, Maryland. 5. Departments of Medicine and Radiology, Johns Hopkins Medicine, Baltimore, Maryland. 6. Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, Washington. 7. Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, Washington; Department of Epidemiology, University of Washington, Seattle, Washington. Electronic address: learyp@uw.edu.
Abstract
BACKGROUND: Soluble Fms-like tyrosine kinase 1 (sFlt-1) may inhibit angiogenesis. Higher levels of sFlt-1 are associated with worse prognosis in prevalent heart failure patients. The aim of this study was to better understand the role of sFlt-1 in heart failure pathogenesis by characterizing relationships between sFlt-1, cardiac morphology, and the composite outcome of incident heart failure or cardiovascular (CV) death in in a multiethnic cohort free of CV disease at baseline. METHODS: sFlt-1 was measured in 1,381 participants in the Multi-Ethnic Study of Atherosclerosis Angiogenesis sub-study. Linear regression was used to estimate the association between sFlt-1 and cardiac morphology and Cox proportional hazard regression was used to estimate associations with incident heart failure or CV mortality. RESULTS: Over a median follow-up of 13.1 years, higher sFlt-1 levels were associated with incident heart failure or CV mortality independent from CV risk factors or NT-proBNP levels (HR 1.17, 95% CI 1.10-1.26, p < 0.001). Higher sFlt-1 levels were also associated with greater baseline left ventricular (LV) mass by cardiac MRI and increased loss of LV mass over the 10 years following the baseline exam (p-value 0.02 for each), but this association was no longer statistically significant after adjustment for baseline NT-proBNP (p = 0.11 and 0.10 respectively). CONCLUSIONS: Baseline sFlt-1 levels are associated with incident heart failure and cardiovascular mortality independent of traditional CV risk factors or NT-proBNP. An association was also found with cardiac mass but was no longer significant after adjustment for NT-proBNP.
BACKGROUND: Soluble Fms-like tyrosine kinase 1 (sFlt-1) may inhibit angiogenesis. Higher levels of sFlt-1 are associated with worse prognosis in prevalent heart failure patients. The aim of this study was to better understand the role of sFlt-1 in heart failure pathogenesis by characterizing relationships between sFlt-1, cardiac morphology, and the composite outcome of incident heart failure or cardiovascular (CV) death in in a multiethnic cohort free of CV disease at baseline. METHODS: sFlt-1 was measured in 1,381 participants in the Multi-Ethnic Study of Atherosclerosis Angiogenesis sub-study. Linear regression was used to estimate the association between sFlt-1 and cardiac morphology and Cox proportional hazard regression was used to estimate associations with incident heart failure or CV mortality. RESULTS: Over a median follow-up of 13.1 years, higher sFlt-1 levels were associated with incident heart failure or CV mortality independent from CV risk factors or NT-proBNP levels (HR 1.17, 95% CI 1.10-1.26, p < 0.001). Higher sFlt-1 levels were also associated with greater baseline left ventricular (LV) mass by cardiac MRI and increased loss of LV mass over the 10 years following the baseline exam (p-value 0.02 for each), but this association was no longer statistically significant after adjustment for baseline NT-proBNP (p = 0.11 and 0.10 respectively). CONCLUSIONS: Baseline sFlt-1 levels are associated with incident heart failure and cardiovascular mortality independent of traditional CV risk factors or NT-proBNP. An association was also found with cardiac mass but was no longer significant after adjustment for NT-proBNP.
Authors: John Eng; Robyn L McClelland; Antoinette S Gomes; W Gregory Hundley; Susan Cheng; Colin O Wu; J Jeffrey Carr; Steven Shea; David A Bluemke; Joao A C Lima Journal: Radiology Date: 2015-10-20 Impact factor: 11.105
Authors: Steven M Kawut; R Graham Barr; João A C Lima; Amy Praestgaard; W Craig Johnson; Harjit Chahal; Kofo O Ogunyankin; Michael R Bristow; Jorge R Kizer; Harikrishna Tandri; David A Bluemke Journal: Circulation Date: 2012-08-29 Impact factor: 29.690
Authors: Elisabeth Kaza; Klemens Ablasser; Dimitrios Poutias; Eric R Griffiths; Fawzy A Saad; Jochen G Hofstaetter; Pedro J del Nido; Ingeborg Friehs Journal: Cardiovasc Res Date: 2010-10-08 Impact factor: 10.787
Authors: Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke Journal: AJR Am J Roentgenol Date: 2006-06 Impact factor: 3.959
Authors: Julie Damp; Michael M Givertz; Marc Semigran; Rami Alharethi; Gregory Ewald; G Michael Felker; Biykem Bozkurt; John Boehmer; Jennifer Haythe; Hal Skopicki; Karen Hanley-Yanez; Jessica Pisarcik; Indrani Halder; John Gorcsan; Sarosh Rana; Zoltan Arany; James D Fett; Dennis M McNamara Journal: JACC Heart Fail Date: 2016-03-09 Impact factor: 12.035
Authors: Ian S Patten; Sarosh Rana; Sajid Shahul; Glenn C Rowe; Cholsoon Jang; Laura Liu; Michele R Hacker; Julie S Rhee; John Mitchell; Feroze Mahmood; Philip Hess; Caitlin Farrell; Nicole Koulisis; Eliyahu V Khankin; Suzanne D Burke; Igor Tudorache; Johann Bauersachs; Federica del Monte; Denise Hilfiker-Kleiner; S Ananth Karumanchi; Zoltan Arany Journal: Nature Date: 2012-05-09 Impact factor: 49.962
Authors: Isabell Yan; Christin S Börschel; Johannes T Neumann; Ngoc A Sprünker; Nataliya Makarova; Jukka Kontto; Kari Kuulasmaa; Veikko Salomaa; Christina Magnussen; Licia Iacoviello; Augusto Di Castelnuovo; Simona Costanzo; Allan Linneberg; Stefan Söderberg; Tanja Zeller; Francisco M Ojeda-Echevarria; Stefan Blankenberg; Dirk Westermann Journal: JACC Heart Fail Date: 2020-03-11 Impact factor: 12.035